The role of resection for patients with renal carcinoma.
Metastatic renal cancer is responsive in some cases to immunotherapeutic agents. Indications for nephrectomy in the face of metastatic disease have traditionally included palliation of symptoms caused by the primary tumor, and nephrectomy combined with metastatectomy in patients with resectable metastases. Recent findings from a Southwest Oncology Group trial strongly suggest that cytoreductive nephrectomy, combined with immunotherapy, may also result in improved survival in patients with unresectable metastases.
Flanigan
R C
RC
Department of Urology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA. rflanig@luc.edu
Yonover
P M
PM
D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000556:secondary / Q000601:surgery*; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D007238:Infarction / Q000276:immunology; D007668:Kidney / Q000098:blood supply; D007680:Kidney Neoplasms / Q000276:immunology / Q000473:pathology / Q000601:surgery*; D009392:Nephrectomy; D011379:Prognosis